Literature DB >> 21713730

Seroprevalence of toxoplasmosis in HIV(+)/AIDS patients in Iran.

Minoo Mohraz1, Farhad Mehrkhani, Sara Jam, SeyedAhmad SeyedAlinaghi, Duman Sabzvari, Fatemeh Fattahi, Hossain Jabbari, Mahboubeh Hajiabdolbaghi.   

Abstract

Toxoplasma gondii has arisen as an important opportunistic agent especially in the central nervous system and in advanced HIV disease can cause significant morbidity and mortality. This study was carried out to determine the seroprevalence of toxoplasmosis among HIV-positive patients in Iran. Blood samples were collected from 201 HIV-positive patients and anti-toxoplasma antibodies were detected by using conventional ELISA. An antibody titer of >3 IU/ml was considered positive. The majority of studied patients were male (male to female ratio: 5 to 1) with the mean age of 36 ± 1 yrs. The seroprevalence of toxoplasmosis in HIV-positive patients was 49.75%. The mean CD4 count in HIV patients with positive toxoplasma serology was 332.5 ± 22.4 cells/µl. Only 1% of the patients had IgM anti-toxoplasma antibodies and 10% of the patients had clinical toxoplasma encephalitis. The mean CD4 count in this group was 66.4 ± 15.5 cells/µl and there was a significant association between CD4 count and rate of toxoplasma encephalitis (P<0.001). Previous reports suggested that toxoplasma encephalitis could be prevented by appropriate chemoprophylaxis. In view of the relatively high prevalence of toxoplasma infection found among the HIV-infected patients in our study, we suggest that routine screening for toxoplasma should be undertaken for all HIV-infected patients in Iran.

Entities:  

Mesh:

Year:  2011        PMID: 21713730

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  8 in total

1.  Comparative study on toxoplasma serology among HIV positive and HIV negative illicit drug users in Ahvaz, Iran.

Authors:  Seyed Mohammad Alavi; Ramin Jamshidian; Shokrolah Salmanzadeh
Journal:  Caspian J Intern Med       Date:  2013

2.  Serological Evaluation of Toxoplasmosis and Related Risk Factors Among HIV+/AIDS Patients in Northern Iran.

Authors:  Hasan Rafati-Sajedi; Bijan Majidi-Shad; Reza Jafari-Shakib; Zahra Atrkar-Roshan; Mohammad Reza Mahmoudi; Seyed Mahmood Rezvani
Journal:  Acta Parasitol       Date:  2021-05-22       Impact factor: 1.440

3.  Seroprevalence and Associated Risk Factors of Toxoplasma gondii in Pregnant Women Attending in Northwest Ethiopia.

Authors:  Mengistu Endris; Yeshambel Belyhun; Feleke Moges; Mulat Adefiris; Zinaye Tekeste; Andargachew Mulu; Afework Kassu
Journal:  Iran J Parasitol       Date:  2014-09       Impact factor: 1.012

4.  Frequency of Toxoplasma gondii in HIV Positive Patients from West of Iran by ELISA and PCR.

Authors:  Ali Rostami; Hossien Keshavarz; Saeedeh Shojaee; Mehdi Mohebali; Ahmad Reza Meamar
Journal:  Iran J Parasitol       Date:  2014 Oct-Dec       Impact factor: 1.012

5.  Downregulated IL-21 Response and T Follicular Helper Cell Exhaustion Correlate with Compromised CD8 T Cell Immunity during Chronic Toxoplasmosis.

Authors:  Magali M Moretto; SuJin Hwang; Imtiaz A Khan
Journal:  Front Immunol       Date:  2017-10-31       Impact factor: 7.561

6.  The Correlation between Serum Levels of Anti-Toxoplasma gondii Antibodies and the Risk of Diabetes.

Authors:  Maryam Khalili; Mahmoud Mahami-Oskouei; Abbas Shahbazi; Abdolrasoul Safaiyan; Nader Mohammadzadeh-Gheshlaghi; Leyla Mahami-Oskouei
Journal:  Iran J Parasitol       Date:  2018 Oct-Dec       Impact factor: 1.012

7.  Prevalence of Toxoplasma gondii Antibodies and DNA in Iranian HIV Patients.

Authors:  Anahita Bavand; Arezoo Aghakhani; Minoo Mohraz; Mohammad Banifazl; Afsaneh Karami; Majid Golkar; Jalal Babaie; Parviz Saleh; Setareh Mamishi; Amitis Ramezani
Journal:  Iran J Pathol       Date:  2018-12-27

8.  High Seroprevalence of Toxoplasma gondii Antibody in HIV/AIDS Individuals from North of Iran.

Authors:  Mohammad Taghi Rahimi; Seif Ali Mahdavi; Behzad Javadian; Rozita Rezaei; Mahmood Moosazadeh; Mehri Khademlou; Seyed Hosein Seyedpour; Abolghasem Syadatpanah
Journal:  Iran J Parasitol       Date:  2015 Oct-Dec       Impact factor: 1.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.